Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.

Details

Ressource 1Download: 27441069_BIB_882998311C4F.pdf (144.69 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_882998311C4F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.
Journal
Rare tumors
Author(s)
Zwahlen D.R., Schick U., Bolukbasi Y., Thariat J., Abdah-Bortnyak R., Kuten A., Igdem S., Caglar H., Ozsaran Z., Loessl K., Khanfir K., Villette S., Vees H.
ISSN
2036-3605 (Print)
ISSN-L
2036-3605
Publication state
Published
Issued date
28/06/2016
Peer-reviewed
Oui
Volume
8
Number
2
Pages
6052
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.
Keywords
Carcinosarcoma, brachytherapy, radiotherapy, toxicity, uterine malignancies
Pubmed
Web of science
Open Access
Yes
Create date
18/10/2019 17:33
Last modification date
15/01/2021 7:10
Usage data